Hemophilia A Pipeline Review, H1 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Hemophilia A - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

Hemophilia A - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia A (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 10, 7, 4, 24, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

Hemophilia A (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Hemophilia A - Overview
  3. Hemophilia A - Therapeutics Development
  4. Hemophilia A - Therapeutics Assessment
  5. Hemophilia A - Companies Involved in Therapeutics Development
  6. Hemophilia A - Drug Profiles
  7. Hemophilia A - Dormant Projects
  8. Hemophilia A - Discontinued Products
  9. Hemophilia A - Product Development Milestones
  10. Appendix

Companies Mentioned

  • Alnylam Pharmaceuticals Inc
  • Amarna Therapeutics BV
  • Apitope International NV
  • Bayer AG
  • BioMarin Pharmaceutical Inc
  • Bioverativ Inc
  • Casebia Therapeutics
  • Catalyst Biosciences Inc
  • Chugai Pharmaceutical Co Ltd
  • CSL Ltd
  • DBV Technologies SA
  • EpiVax Inc
  • Expression Therapeutics LLC
  • GC Pharma
  • ID Pharma Co Ltd
  • Idogen AB
  • Immusoft Corp
  • Innovare R & D SA De CV
  • LFB SA
  • mAbxience SA
  • Novo Nordisk AS
  • Okklo Life Sciences BV
  • OPKO Biologics Ltd
  • Pangen Biotech Inc.
  • Pfizer Inc
  • Pharming Group NV
  • Promethera Biosciences SA
  • Sangamo Therapeutics Inc
  • Shire Plc
  • Sino Biopharmaceutical Ltd
  • SK Chemicals Co Ltd
  • Spark Therapeutics Inc
  • Ultragenyx Pharmaceutical Inc
  • UniQure NV
  • XL-protein GmbH

For more information about this report visit https://www.researchandmarkets.com/research/rgbmt4/hemophilia_a?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematological Drugs